Hansa Biopharma AB Cash Flow Reinvestment Rate
Latest as of September 2020:
3.23x
Hansa Biopharma AB cash flow reinvestment rate. Hansa Biopharma AB (HNSA) has a Cash Flow Reinvestment Rate of 3.23x as of September 2020, reinvesting Skr15.60 Million (capex Skr683.00K plus investments Skr14.91 Million) from operating cash flow of Skr4.83 Million. Explore cash flow to debt ratio of Hansa Biopharma AB to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
3.23x
(Capex + Investments) / Operating CF
Total Reinvested
Skr15.60 Million
Capex + Investments
Operating Cash Flow
Skr4.83 Million
SEK
Capital Expenditures
Skr683.00K
SEK
Hansa Biopharma AB Cash Flow Reinvestment Rate by Year (None–None)
Hansa Biopharma AB cash flow reinvestment rate by year from None to None. Year-by-year capital reinvestment analysis for Hansa Biopharma AB. For the full cash flow conversion analysis, see Hansa Biopharma AB operating cash flow efficiency.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow